CAR-T cell therapy for lung cancer: a promising but challenging future.
作者信息
Zhong Shupeng, Cui Yingqiang, Liu Qian, Chen Size
机构信息
Department of Oncology, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Provincial Engineering Research Center for Esophageal Cancer Precision Treatment, Guangzhou 510080, China.
Central Laboratory, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Provincial Engineering Research Center for Esophageal Cancer Precision Treatment, Guangzhou 510080, China.
出版信息
J Thorac Dis. 2020 Aug;12(8):4516-4521. doi: 10.21037/jtd.2020.03.118.
Abstract
摘要
相似文献
1
CAR-T cell therapy for lung cancer: a promising but challenging future.用于肺癌的嵌合抗原受体T细胞疗法：前景光明但充满挑战的未来。
J Thorac Dis. 2020 Aug;12(8):4516-4521. doi: 10.21037/jtd.2020.03.118.
2
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.嵌合抗原受体 T 细胞靶向 EGFRvIII 治疗转移性肺癌。
Front Med. 2019 Feb;13(1):57-68. doi: 10.1007/s11684-019-0683-y. Epub 2019 Feb 5.
3
Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.EGFR 特异性 CAR T 细胞在体外和小鼠体内对非小细胞肺癌细胞的抗肿瘤活性。
Cell Death Dis. 2018 Feb 7;9(2):177. doi: 10.1038/s41419-017-0238-6.
4
LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer.LunX嵌合抗原受体T细胞作为非小细胞肺癌的靶向治疗方法
Mol Ther Oncolytics. 2020 Apr 21;17:361-370. doi: 10.1016/j.omto.2020.04.008. eCollection 2020 Jun 26.
5
Establishing guidelines for CAR-T cells: challenges and considerations.制定 CAR-T 细胞治疗指南：挑战与考量。
Sci China Life Sci. 2016 Apr;59(4):333-9. doi: 10.1007/s11427-016-5026-5. Epub 2016 Mar 11.
6
Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.嵌合抗原受体修饰的T细胞可抑制NOG小鼠体内已形成的组织因子阳性肿瘤的生长和转移。
Oncotarget. 2017 Feb 7;8(6):9488-9499. doi: 10.18632/oncotarget.14367.
7
Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.嵌合抗原受体 (CAR) T 细胞治疗的进展：现状与展望。
Arch Pharm Res. 2019 Jul;42(7):607-616. doi: 10.1007/s12272-019-01136-x. Epub 2019 Mar 4.
8
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.基于 CAR 的策略超越 T 淋巴细胞：癌症过继免疫治疗的综合机会。
Int J Mol Sci. 2019 Jun 11;20(11):2839. doi: 10.3390/ijms20112839.
9
Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion.白细胞介素-7的共表达通过增强增殖、抑制凋亡和耗竭来改善基于自然杀伤细胞2D受体的嵌合抗原受体T细胞疗法对前列腺癌的治疗效果。
Cancers (Basel). 2020 Jul 20;12(7):1969. doi: 10.3390/cancers12071969.
10
CAR T-cells for cancer therapy.嵌合抗原受体 T 细胞疗法用于癌症治疗。
Biotechnol Genet Eng Rev. 2017 Oct;33(2):190-226. doi: 10.1080/02648725.2018.1430465. Epub 2018 Feb 12.
引用本文的文献
1
Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review.纳米颗粒增强型CAR-T和NK细胞疗法在肿瘤学中的临床试验：克服转化和临床挑战——一篇综述
Front Med (Lausanne). 2025 Aug 6;12:1655693. doi: 10.3389/fmed.2025.1655693. eCollection 2025.
2
Towards the development of next-generation lung cancer immunotherapy.迈向新一代肺癌免疫疗法的发展
Transl Lung Cancer Res. 2025 Jun 30;14(6):2257-2271. doi: 10.21037/tlcr-2024-1097. Epub 2025 Jun 25.
3
Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess.五种抗头颈部鳞状细胞癌药物的不良事件概况：来自世界卫生组织药物警戒数据库VigiAccess的描述性分析
Front Pharmacol. 2025 Jun 24;16:1602276. doi: 10.3389/fphar.2025.1602276. eCollection 2025.
4
Smart nanomedicines powered by artificial intelligence: a breakthrough in lung cancer diagnosis and treatment.由人工智能驱动的智能纳米药物：肺癌诊断与治疗的一项突破。
Med Oncol. 2025 Mar 25;42(5):134. doi: 10.1007/s12032-025-02680-x.
5
Immune Effector Cell-Associated Neurotoxicity Syndrome After CAR T-Cell Therapy and Other Psychiatric Manifestations: A Review and Case Series.CAR-T细胞治疗后免疫效应细胞相关神经毒性综合征及其他精神症状：综述与病例系列
J Clin Med. 2025 Feb 21;14(5):1451. doi: 10.3390/jcm14051451.
6
Non-targeted effects of stereotactic radiotherapy: a review of the evidence coming from the clinical field.立体定向放射治疗的非靶向效应：来自临床领域证据的综述
Explor Target Antitumor Ther. 2025 Feb 13;6:1002290. doi: 10.37349/etat.2025.1002290. eCollection 2025.
7
Adopting tomorrow's therapies today: a perspective review of adoptive cell therapy in lung cancer.今日采用明日之疗法：肺癌过继性细胞疗法的前瞻性综述
Ther Adv Med Oncol. 2025 Feb 24;17:17588359251320280. doi: 10.1177/17588359251320280. eCollection 2025.
8
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures.在表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKI）和免疫选择压力下克隆驱动新抗原的丢失
Nature. 2025 Mar;639(8056):1052-1059. doi: 10.1038/s41586-025-08586-y. Epub 2025 Feb 19.
9
The Role of Immunotherapy in Lung Cancer Treatment: Current Strategies, Future Directions, and Insights into Metastasis and Immune Microenvironment.免疫疗法在肺癌治疗中的作用：当前策略、未来方向以及对转移和免疫微环境的见解
Curr Gene Ther. 2025 Jan 6. doi: 10.2174/0115665232340926241105064739.
10
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.程序性死亡受体1（PD-1）阻断疗法并不能提高靶向上皮细胞黏附分子（EpCAM）的嵌合抗原受体（CAR）T细胞治疗肺癌脑转移的疗效。
Cancer Immunol Immunother. 2024 Oct 3;73(12):255. doi: 10.1007/s00262-024-03837-9.
本文引用的文献
1
PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges.PD-1 阻断 CAR-T 细胞治疗实体瘤：前景与挑战。
Biomed Pharmacother. 2020 Jan;121:109625. doi: 10.1016/j.biopha.2019.109625. Epub 2019 Nov 13.
2
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.逻辑门控 ROR1 嵌合抗原受体表达挽救了 T 细胞对正常组织的细胞毒性，并实现了肿瘤的选择性靶向。
Cancer Cell. 2019 Mar 18;35(3):489-503.e8. doi: 10.1016/j.ccell.2019.02.003.
3
NR4A transcription factors limit CAR T cell function in solid tumours.NR4A 转录因子限制了 CAR T 细胞在实体瘤中的功能。
Nature. 2019 Mar;567(7749):530-534. doi: 10.1038/s41586-019-0985-x. Epub 2019 Feb 27.
4
DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells.DNAX激活蛋白10共刺激增强嵌合抗原受体T细胞的抗肿瘤功效。
Oncoimmunology. 2018 Nov 2;8(1):e1509173. doi: 10.1080/2162402X.2018.1509173. eCollection 2019.
5
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.抗 PD-1/PD-L1 治疗非小细胞肺癌：迈向个体化医学和联合策略。
J Immunol Res. 2018 Aug 8;2018:6984948. doi: 10.1155/2018/6984948. eCollection 2018.
6
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.CAR-T 细胞靶向递送 PD-1 阻断 scFv 增强体内抗肿瘤疗效。
Nat Biotechnol. 2018 Oct;36(9):847-856. doi: 10.1038/nbt.4195. Epub 2018 Aug 13.
7
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
8
T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.T 细胞归巢治疗减少大型实体瘤中的调节性 T 细胞并保留效应 T 细胞功能。
Clin Cancer Res. 2018 Jun 15;24(12):2920-2934. doi: 10.1158/1078-0432.CCR-17-1365. Epub 2018 Feb 1.
9
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.第一代癌胚抗原（CEACAM5）特异性嵌合抗原受体T细胞的临床疗效受到持久性差和短暂的预处理依赖性呼吸毒性的限制。
Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28.
10
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.用于肺癌和恶性胸膜间皮瘤的嵌合抗原受体T细胞疗法。
Transl Res. 2017 Sep;187:1-10. doi: 10.1016/j.trsl.2017.04.004. Epub 2017 Apr 26.
Zotero 插件